ArticleJournal of nanobiotechnology2026
NK cell vesicles-based nanoplatform loaded with sorafenib synergizing ferroptosis and antitumor immunity against hepatocellular carcinoma.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundFerroptosis is a type of cell death that relies on iron and is marked by an excess of intracellular iron and the buildup of lipid peroxides. This process presents a new and promising approach for cancer treatment. Improving ferroptosis can effectively mitigate the limitations of conventional treatment methods.
methodsWe developed a synergistic nanotherapeutic platform. Natural killer cell derived nanovesicles (NK-NVs) were fabricated using an extrusion method and subsequently loaded with sorafenib (SRB) via electroporation, resulting in the NK-NVs-SRB complex for targeted delivery.
resultsThe therapeutic strategy not only escaped recognition by drug efflux pumps, thus lowering drug expulsion, but also effectively triggered ferroptosis in cancer cells. This process induced significant release of damage associated molecular patterns (DAMPs), ultimately leading to immunogenic cell death (ICD). In vivo experiments demonstrated that NK-NVs-SRB intervention achieved a tumor growth inhibition rate of 44.54%, effectively drove the ferroptosis process, and activated anti-tumor immunity by recruiting CD8 + T cell infiltration.
conclusionsThis study proposes a novel therapeutic strategy for hepatocellular carcinoma (HCC) that acts by synergistically inducing ferroptosis and activating anti-tumor immunity, thereby paving a new avenue for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.